Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Mefloquine Hydrochloride

Add time:07/20/2019    Source:sciencedirect.com

ABSTRACTLiterature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing mefloquine hydrochloride as the only active pharmaceutical ingredient (API) are reviewed. The solubility and permeability data of mefloquine hydrochloride as well as its therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability studies were taken into consideration. Mefloquine hydrochloride is not a highly soluble API. Since no data on permeability are available, it cannot be classified according to the Biopharmaceutics Classification System with certainty. Additionally, several studies in the literature failed to demonstrate BE of existing products. For these reasons, the biowaiver cannot be justified for the approval of new multisource drug products containing mefloquine hydrochloride. However, scale-up and postapproval changes (HHS-FDA SUPAC) levels 1 and 2 and most EU type I variations may be approvable without in vivo BE, using the dissolution tests described in these regulatory documents.

We also recommend Trading Suppliers and Manufacturers of 2-(3-Piperidyl)ethanol Hydrochloride (cas 16780-04-4). Pls Click Website Link as below: cas 16780-04-4 suppliers

Prev:Synthesis and biological characterization of stable and radioiodinated (±)-trans-2-hydroxy-3-P{4-(3-iodophenyl)piperidyl}-1,2,3,4-tetrahydronaphthalene (3′-IBVM)
Next:Compressibility, isothermal titration calorimetry and dynamic light scattering analysis of the aggregation of the amphiphilic phenothiazine drug thioridazine hydrochloride in water/ethanol mixed solvent)